Wall street beats to host conference call with sarepta ceo on ground-breaking expanded label approval

San diego--(business wire)--wall street beats is pleased to announce an investor conference call with doug ingram, ceo of sarepta therapeutics, following the landmark fda approval expanding the label for elevidys (delandistrogene moxeparvovec-rokl) to treat duchenne muscular dystrophy (dmd) patients aged four and above. the call will be hosted by david maris, a six-time #1 ranked pharma analyst and partner at wall street beats. maris stated, "sarepta's expanded label approval for elevidys is a.
SRPT Ratings Summary
SRPT Quant Ranking